Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP patients (46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to a neoplastic disease subtype: lymphoproliferative disorders [LPDs] and 18 with ITP secondary to viral infections) who had been treated with eltrombopag were retrospectively evaluated. Forty-four patients (38%) had a platelet response, including 40 (35%) with complete responses. Median time to platelet response was 15 days (95% confidence interval, 7-28 days), and was longer in the LPD-ITP group. Platelet response rate was significantly lower in the LPD-ITP than in other groups. However, having achieved response, there were no significant differences between the durable response of the groups. Forty-three patients (49Á4%) experienced adverse events (mainly grade 1-2), the commonest being hepatobiliary laboratory abnormalities. There were 10 deaths in this case series, all of which were related to pre-existing medical conditions. In routine clinical practice, eltrombopag is effective and well-tolerated in unselected patients with ITP secondary to both immune and infectious disorders. However, the response rate in LPD-ITP is low.
Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by the accelerated destruction and inadequate production of platelets that is mediated by antibodies (Toltl & Arnold, 2011) . ITP may be primary or secondary to an underlying disorder. Some common and well-characterized conditions associated with ITP are infections, autoimmune diseases, cancer and drugs (Kistangari & McCrae, 2013) . ITP secondary to medical conditions usually presents with an insidious onset and has no tendency to remit spontaneously, although the severity of the thrombocytopenia may parallel the stage of the underlying condition (Stasi, 2009) . The management of thrombocytopenia in secondary immune thrombocytopenia patients is difficult, and corticosteroids and splenectomy are less effective than in primary immune thrombocytopenia (Arnal et al, 2002; Visco et al, 2008) . Also, for thrombocytopenias secondary to an ongoing medical condition, treatment is often targeted toward the underlying disorder (Stasi, 2009) .
Thrombopoietin receptor agonists (THPO-RA), such as romiplostim and eltrombopag, represent a new approach to the treatment of primary ITP. Eltrombopag is an oral, nonpeptide THPO-RA that binds to a transmembrane site on the thrombopoietin receptor and increases the number of platelets. It has been consolidated as a second-or third-line treatment for primary ITP (Neunert et al, 2011) . Also, eltrombopag is currently approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of thrombocytopenia secondary to aplastic anaemia (Olnes et al, 2012) and thrombocytopenia secondary to hepatitis C infection (McHutchison et al, 2007; Afdhal et al, 2012) . Eltrombopag has also been successfully used in a very small number of patients with immune thrombocytopenia secondary to chronic lymphatic leukaemia (Koehrer et al, 2010; Sinisalo et al, 2011; Gudbrandsdottir et al, 2012; Jolliffe & Romeril, 2014; Chang & Shih, 2015) , systemic lupus erythematosus (SLE: Chang & Shih, 2015; Gonzalez-Nieto et al, 2011; Alkaabi et al, 2012; Scheinberg et al, 2014; Magnano et al, 2014; Maroun et al, 2015) , Evans syndrome (GonzalezNieto et al, 2011; Alkaabi et al, 2012; Ruiz-Arguelles et al, 2013; Magnano et al, 2014; Scheinberg et al, 2014; Chang & Shih, 2015; Maroun et al, 2015) , human immunodeficiency virus (Quach et al, 2012; Aslam et al, 2014; Chang & Shih, 2015; Kowalczyk et al, 2015) and coeliac disease (Chang & Shih, 2015) who had a loss of response to standard treatment for ITP. The communication of such cases is essential to support the potential utility of eltrombopag as salvage therapy in the treatment of secondary immune thrombocytopenia. The aim of the present study is to determine the efficacy and safety of eltrombopag in secondary immune thrombocytopenia in everyday clinical practice.
Materials and methods

Patients and study design
Eighty-seven secondary ITP patients (aged at least 18 years) from 23 Spanish centres who had been treated with eltrombopag were retrospectively evaluated. Clinical charts were reviewed by the researchers, who collected the clinical and biological characteristics of each patient in the study by means of a predetermined case report form. Patient and disease characteristics, including age, gender, months since diagnosis, type of therapies prior to starting eltrombopag, platelet counts (at diagnosis, and before and during eltrombopag treatment), dose and duration of eltrombopag treatment, and adverse events during the treatment, were recorded. Secondary ITP was defined as all forms of immunemediated thrombocytopenia (a platelet count of <100 9 10 9 /l) secondary to an underlying disorder . We included immune thrombocytopenia secondary to autoimmune diseases, viral infections and lymphoproliferative disorders. In all patients, factors involved in non-immune thrombocytopenia, such as splenomegaly, drugs or impaired production by tumours, were excluded. The diagnosis of ITP secondary to lymphoproliferative disorders required all of the following criteria (Visco & Rodeghiero, 2009 ): acute (<2 weeks) and severe thrombocytopenia with a normal or augmented number of megakaryocytes in the bone marrow and the absence of splenomegaly, infection or cytotoxic treatments in the previous month. The diagnosis of ITP secondary to autoimmune disorders or infections was defined as isolated and severe thrombocytopenia (at least half of the initial level and below 100 9 10 9 /l) with a normal peripheral blood film in the presence of already established autoimmune disorder or viral infection related to immune thrombocytopenia that cannot be explained by other medical conditions or treatments. A lack of response to platelet transfusion or a rapid response (<1 week) to high-dose intravenous immunoglobulin (IVIg) was considered essential requirements for the diagnosis of ITP. Eltrombopag was initiated on the basis of the clinical judgment of the treating physicians of secondary ITP patients who had a loss of response to standard treatment for ITP. Eltrombopag was administered at doses of 25-75 mg/day.
Endpoints
Complete response (CR) was defined as a platelet count of ≥100 9 10 9 /l. Response (R) was defined as a platelet count of 30-100 9 10 9 /l and at least twice the baseline count. No response (NR) was defined as a platelet count of <30 9 10 9 /l or less than twice the baseline count . The definition of response required concurrent resolution of bleeding symptoms and the absence of any rescue intervention during the preceding 8 weeks. Durable response was measured as achieving weekly platelet responses (platelet counts of 50 9 10⁹/l without rescue medication use in the preceding 4 weeks) in six or more of the final 8 weeks (Tarantino et al, 2016) . Treatment failure was defined as a platelet count of ≤ 20 9 10 9 /l for four consecutive weeks at the highest recommended dose of eltrombopag, a major bleeding event, or the need to change therapy (including splenectomy and rescue treatment). The need to increase the dose of a concomitant treatment to eltrombopag at higher levels of the baseline dose was considered a rescue treatment. We evaluated and classified the adverse events with eltrombopag according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).
Ethical aspects
The study was performed in accordance with the guidelines of the institutional review boards of the participating centres and the standards of the Helsinki Declaration. 
Results
Patient characteristics
Of the first 87 Spanish patients enrolled in this study who received eltrombopag, 46 were treated for ITP secondary to autoimmune syndromes, 23 for ITP secondary to a subtype of neoplastic disease [lymphoproliferative disorders (LPDs)] and 18 had ITP secondary to viral infections. The underlying disorders resulting in ITP were as follows: hepatitis C virus (HCV) in 16 cases, SLE in 13 cases 8 Evans syndrome, 6 antiphospholipidic syndromes, 6 chronic lymphocytic leukaemia (CLL), 6 plasma cell neoplasms, 5 human immunodeficiency virus (HIV), 4 Sj€ ogren syndrome, 4 patients with other lymphoma types, 3 cases of rheumatoid arthritis, 3 immunodeficiencies, 2 HIV-HCV coinfections, 2 autoimmune hepatitis, 2 patients with primary biliary cirrhosis, 1 psoriatic arthritis, 1 Graves-Basedow disease (an autoimmune disease that affects the thyroid; the most common cause of hyperthyroidism) and 1 case of inflammatory bowel disease. The cohort also included 1 case of HIV-Lymphoma, 1 patient with HCV-Lymphoma, 1 patient with Evans Syndrome-Immunodeficiency and 1 patient with Evans Syndrome-HCV. The main demographic and haematological features of the 87 patients who received eltrombopag are presented in Table I median time with a secondary-ITP diagnosis was 14 months (IQR, 2-68 months). A median of two therapies (IQR, 2-3) were used to treat thrombocytopenia prior to administration of eltrombopag; these included rituximab (23%) and splenectomy (21%). At the time of starting eltrombopag treatment, 52 patients (60%) were receiving concomitant treatment for ITP, mainly consisting of corticosteroids and/ or immunoglobulins. The median platelet count at the time eltrombopag treatment was started was 14 9 10 9 /l (IQR, 7-26 9 10 9 /l). 40 patients (46%) showed signs of bleeding during the month before starting their treatment with eltrombopag. The Charlson comorbidity index and the number of prior therapies were significantly lower in the group with infectious diseases related to ITP than in the other two groups.
Eltrombopag efficacy
Forty-four of the 87 patients (38%) had a platelet response, including 35% (n = 40) of cases with CR. Platelet response and the proportions achieving CR varied in the different diagnostic groups. Significantly lower levels of platelet Bleeding at start of eltrombopag treatment, n (%) 40 (46) 24 (59) 7 (30) 9 (50) 0Á171 Concomitant treatment at start of eltrombopag treatment, n (%)
52 (60) 29 (63) 10 (45) 13 (72) 0Á198 Corticoids 35 (40) 20 (43) 7 (30) 8 (44) 0Á224 Immunoglobulin 6 (7) 5 (11) 1 (4) 0 (0) 0Á259 Corticoids plus immunoglobulin 6 (7) 3 (7) 3 (13) 
ITP, immune thrombocytopenia; LPD, lymphoproliferative disease; Q1;Q3, interquartile range. Statistical significance: a value of P < 0Á05 indicates a significant difference between at least two groups, although the test does not identify which groups are involved. was much shorter than observed in the infectious and LPD groups (43 and 44 days, respectively). Three months after eltrombopag initiation, the platelet response rate was significantly higher in patients with ITP related to infectious disorders (70%) than in other groups (52% in immune disorders and only 12Á5% in LPD group). However, there were no significant differences in the durable responses of the groups (Fig 2) . Notably, eight patients (5 infectious -ITP; 3 immune-ITP and 1 LPD-ITP) who achieved CR with eltrombopag sustained platelet response. After a median follow-up of 11 months (IQR, 5-22 months), 5 of 44 patients who responded to eltrombopag had relapsed. The median time to relapse was 4 months (IQR, 3-6 months).
Platelet response to eltrombopag according to previous ITP and underlying disease treatments is described separately for the immune (Table III) , infectious (Table IV) and neoplastic (LPD) ( Table V) groups.
Eltrombopag safety
Of the 87 patients, 35 (40Á2%) experienced one or more adverse events during treatment with eltrombopag. Eleven (12Á6%) experienced adverse events of grade 3-4 in severity (Table VI) . The commonest adverse effects reported during eltrombopag treatment were hepatobiliary laboratory abnormalities (HBLAs) (4Á6%), thrombosis (4Á6%), and diarrhoea (3Á4%). Four patients, all with ITP secondary to immune disorders, had HBLA. One of them developed a grade III HBLA. Liver function tests were resolved in all patients (three were able to continue their treatment, but one had to discontinue eltrombopag). Four patients with cardiovascular risk factors and ITP secondary to immune disorders suffered from thrombotic complications (1 case each of superficial phlebitis, deep venous thrombosis (DVT), pulmonary embolism (PE) and ischaemic stroke). None of these four patients had thrombocytosis at the time of their thrombosis episode. Three of them were in CR when thrombosis was diagnosed (median platelet count of 132 9 10 9 /l) and were receiving eltrombopag treatment (two patients at 50 mg per day; one at 75 mg per day). The DVT episode occurred in a patient with ITP secondary to a marginal lymphoma, with both diseases in CR. Two antiphospholipid syndrome (APS) patients developed thrombosis: superficial phlebitis and PE, respectively. Both had reported previous eltrombopag-unrelated episodes. Ischaemic stroke episode occurred in an SLE patient in response (58 9 10 9 /l) to his disease with an off-label dose of eltrombopag (100 mg/day). The patient with ITP secondary to Evans Syndrome-HCV, without bone marrow specimen collected at baseline, developed grade III myelofibrosis (MF) (an increase in reticulin grade), but after cessation of eltrombopag this decreased to grade I.
There were 10 deaths in this series of cases, all of which were related to pre-existing medical conditions. Four patients died from neoplasms, three of whom were immune ITP patients. One Evans syndrome patient died of a glioblastoma multiforme with ITP in CR nine months after successfully having discontinued eltrombopag treatment. A rheumatoid arthritis patient in whom eltrombopag failed, developed a lung cancer while he was receiving high doses of immunosuppressive drugs and died 23 months after stopping THPO-RA. An antiphospholipidic syndrome patient developed an acute myeloid neoplasm during tapering of eltrombopag treatment at the point when she was receiving only 25 mg per 48 h. The fourth neoplasm exitus was a multiple myeloma patient who had stopped eltrombopag after an inefficient three-month therapy and who died of her underlying disease with ITP in response.
Three patients with LPD-ITP died from sepsis during chemotherapy treatment, and three other deaths were related to refractory thrombocytopenia and severe bleeding (one episode of cerebral haemorrhage in a patient with LPD-ITP; one episode of lung haemorrhage in a previous pulmonary affectation patient who suffered from Evans syndrome and one major bleed in another Evans syndrome patient).
Discussion
Eltrombopag is effective and well tolerated in primary ITP according to pivotal trials (Cheng et al, 2011; Saleh et al, 2013) . In addition, our results from an extra-clinical trial are consistent with the excellent results for eltrombopag obtained in ITP clinical trials (Gonzalez-Porras et al, 2015; GonzalezLopez et al, 2016) . However, the role of eltrombopag in secondary ITP has not been thoroughly studied. This study of the Spanish population is, as far as we know, the largest realworld investigation of eltrombopag treatment in secondary ITP. We describe eltrombopag efficacy and safety during this 11-month follow-up in a clinical practice group of 87 adults with secondary ITP. Our results demonstrated that eltrombopag might be an effective therapy in patients with ITP ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; Angioimm. lymph., angioimmunoblastic lymphadenopathy; Bendam, bendamustine; Bort, bortizumab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; CLL, chronic lymphocytic leukaemia; CR, complete response; CS, corticosteroids; CYC, cyclophosphamide; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ITP, immune thrombocytopenia; IVIG, intravenous immunoglobulin; Lena, lenadolidomide; LPD, lymphoproliferative disease; MM, multiple myeloma; NR, no response; NS, not specified; PTL, peripheral T-cell lymphoma; R, response; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; RCVP, rituximab. Cyclophosphamide; vincristine, prednisolone; RTX, rituximab; WM, Waldenstr€ om macroglobulinaemia.
secondary to both immune and infectious disorders who had a loss of response to standard treatment for ITP. Definition of secondary ITP may appear simple, but in fact it is not. According to the International Working Group for the Standardization of ITP ) the term secondary ITP was proposed in order to include all forms of immune-mediated thrombocytopenias except primary ITP. Immune thrombocytopenia is a diagnosis of exclusion, in which underlying diseases causing immune thrombocytopenia, including viral infections, lymphoproliferative and myeloproliferative disorders, pregnancy, immunodeficiency and autoimmune disorders, must be excluded. Diagnosis of secondary ITP in some cases may be complex in settings in which other causes of thrombocytopenia are quite likely to be contributory. Lack of sensitivity and specificity of platelet autoantibody prevent us from distinguishing the origin of thrombocytopenia (Warner et al, 1999) , which therefore demands the search for standardized clinical criteria and reliable biological tests to distinguish ITP from nonimmune causes of thrombocytopenia.
We have examined 87 patients with a diagnosis of secondary ITP; 46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to LPDs, and 18 with ITP secondary to viral infections. All common causes of thrombocytopenia were taken into account and ruled out before making the diagnosis of secondary ITP. We used rigorous diagnostic criteria. In fact, 50% of patients showed rapid but transient platelet response after receiving a high dose of immunoglobulin.
The published experience of THPO-RAs in secondary ITP is summarized in Table VII . Recently, the Danish experience reported seven cases of secondary ITP (CLL, SLE, Evans syndrome, human immunodeficiency virus and celiac disease) treated with THPO-RAs (Gudbrandsdottir et al, 2012) . In this case series, initial response to THPO-RAs, defined as platelet counts >30 9 10 9 /l after 4 weeks of treatment, was found in 51% of the patients. One of three patients with CLL-ITP responded to eltrombopag. Likewise, we have shown that the response rate to eltrombopag is lower in LPD-ITP than in ITP secondary to immune or infectious disorders. ITP is very common in autoimmune disorders. For example, immune thrombocytopenia occurs in up to 30% of cases of SLE (Arnal et al, 2002) . There are very few reported cases of ITP secondary to autoimmune disorders successfully treated with THPO-RAs. (Gonzalez-Nieto et al, 2011; Alkaabi et al, 2012; Ruiz-Arguelles et al, 2013; Magnano et al, 2014; Scheinberg et al, 2014; Chang & Shih, 2015; Maroun et al, 2015) Here we report an excellent response in ITP secondary to autoimmune disorders. Similarly, the response rate in ITP secondary to infectious disorders was excellent. Previous limited cases have been reported (Ochoa et al, 2011; Quach et al, 2012; Aslam et al, 2014; Chang & Shih, 2015; Kowalczyk et al, 2015) .
A few very promising studies (Visco et al, 2008; Koehrer et al, 2010; Jolliffe & Romeril, 2014; Chang & Shih, 2015) have reported successful eltrombopag use in CLL)associated ITP. Here we report quite low response rates in our LPD patients, which probably reflect the high refractoriness of our patients to different chemotherapy regimens (70% of LPD-ITP patients had received three or more such lines of treatment). Many of them were receiving treatment for ITP and their underlying disease at the same time, which may have reduced LPD-ITP response rates. On the other hand, only six of our 18 LPD patients had CLL. To the best of our knowledge, no cases of eltrombopag use in LPDs other than CLL have been reported to date. Thus, this study raises for the first time, the possibility of using THPO-RAs in this setting.
Eltrombopag was well tolerated in this extra-clinical trial study as well as in the clinical trial of primary ITP. Clinical trials of eltrombopag in primary ITP showed an adverse event profile similar to that with placebo (Saleh et al, 2013) . Here, adverse events were mainly grade 1-2 in severity and the commonest adverse effects were HBLA and thrombosis. No deaths were considered to have been produced by the eltrombopag treatment. Three patients developed neoplasms (glioblastoma multiforme, lung cancer and acute myeloid leukaemia) with subsequent death: two of them had been off eltrombopag therapy for a long time when the cancer appeared. The third patient was receiving very low doses of eltrombopag, so we do not consider it is related to the appearance of the leukaemia. Four patients (4Á6%) had one or more HBLA. Overall, treatment with eltrombopag is infrequently associated with HBLAs (Sinisalo et al, 2011; Gudbrandsdottir et al, 2012; Jolliffe & Romeril, 2014; Chang & Shih, 2015) . These adverse events may appear at any time during treatment but are mostly mild, reversible, and not accompanied by clinically significant symptoms indicative of impaired liver or bone marrow function. In the EXTEND study (Saleh et al, 2013) , 5% of patients with chronic primary ITP who were treated with eltrombopag experienced thromboembolic events. A recent updated meta-analysis has suggested that THPO-RAs in adults with thrombocytopenia are associated with a higher risk of thromboembolic events than in controls (Catal a-L opez et al, 2015) . However, we must bear in mind that primary immune thrombocytopenia is a thrombophilic disorder (Rodeghiero, 2016) , and age, splenomegaly, comorbidity and personal risk (1) factors could further increase the thrombotic risk. There were four episodes of thrombotic events (4Á6%) in our case series of secondary ITPs. All four patients had pre-existing cardiovascular factors. Unfortunately, no well-designed trials evaluating the thrombotic risk of eltrombopag have been reported. Until such trials are undertaken, the thrombotic risk to patients should be taken into account, and whether the benefits of eltrombopag outweigh its risks.
The main limitations of our study are (i) the multicentre retrospective analytical approach and the possibility of major selection bias; (ii) the difficulty of making a diagnosis of secondary ITP (a diagnosis of exclusion) in circumstances in which other causes of thrombocytopenia may be involved; (iii) the lack of clear evidence to ensure the efficacy of eltrombopag alone for secondary ITP patients, given that treatment of the underlying disease may induce a delayed platelet response. For these reasons, and because few patients have yet been described in the medical literature, we cannot draw definitive conclusions about the efficacy or safety of these agents in secondary ITP.
In summary, in daily clinical practice, eltrombopag is effective and well tolerated in unselected patients with ITP secondary to both immune and infectious disorders. However, the response rate in LPD-ITP is low.
